Seattle Genetics Inc. (SGEN)

SGEN (NASDAQ:Drugs)
$38.84
pos +0.00
+0.00%
Today's Range: 38.00 - 40.24 | SGEN Avg Daily Volume: 1,185,100
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 0
YTD Performance: -2.63%
Open: $0.00
Previous Close: $38.57
52 Week Range: $28.15 - $55.99
Oustanding Shares: 122,982,860
Market Cap: 4,781,568,785
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 3 3 4 5
Moderate Sell 1 1 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.89 2.89 2.78 2.80
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -104.80
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-104.80 0.00 29.08
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-19.00% 8.37% 148.50%
GROWTH 12 Mo 3 Yr CAGR
Revenue 27.70 1.51 0.35
Net Income 0.00 -0.06 0.00
EPS 0.00 -0.23 0.00
Earnings for SGEN:
EBITDA -0.05B
Revenue 0.27B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $-0.20 $-0.23 $-0.98 $-0.67
Number of Analysts 9 8 10 8
High Estimate $-0.11 $-0.20 $-0.85 $-0.39
Low Estimate $-0.24 $-0.25 $-1.07 $-0.94
Prior Year $-0.14 $-0.06 $-0.51 $-0.98
Growth Rate (Year over Year) -39.68% -287.50% -91.96% 31.31%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
For these kinds of growth stocks, you have no choice but to wait.
Here are some specific stocks working as parables right now.
It's sardonic, corroded commentary designed to keep your pole in the boat.
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.

Earnings Roundup Real Money Pro($)

Here is my compilation of last night's profit reports.
Bearish
Feb 13, 2013 | 7:23 AM EST
SGEN was downgraded from Buy to Hold, Needham said. Adcetris sales are lagging expectations.   
Bullish
Nov 13, 2012 | 7:17 AM EST
SGEN was initiated with an Outperform rating, Credit Suisse said. $28 price target. Company is a market leader and can continue to grow...
Bearish
Nov 08, 2012 | 7:02 AM EST
SGEN was downgraded from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected.   ...
Bearish
Sep 07, 2012 | 9:08 AM EDT
Shares of SGEN downgraded to Perform from Outperform, Oppenheimer said. $27 price target. Valuation call.

Columnist Conversations

It's been a strong month for oil so far, but as we come out of the holiday weekend, it is likely that we will ...
WMT's new domestic-store only, money transfer service looks to be a brilliant move. The retailer is undercutti...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.